依达拉奉右莰醇治疗急性缺血性脑卒中的药物经济学评价  

Pharmacoeconomic Evaluation of Edaravone Dexborneol in the Treatment of Acute Ischemic Stroke

作　　者：张美燕 张红楠 武小琦 付淑莲[1] 张卓[1] 张磊[1] ZHANG Meiyan;ZHANG Hongnan;WU Xiaoqi;FU Shulian;ZHANG Zhuo;ZHANG Lei(Dept.of Pharmacy,the First Hospital of Hebei Medical University,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第一医院药剂科,石家庄050000

出　　处：《中国医院用药评价与分析》2023年第12期1499-1503,共5页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:利用真实世界数据,评价依达拉奉右莰醇治疗急性缺血性脑卒中的疗效及药物经济性价值,以期为我国脑卒中临床治疗的合理用药和政府决策提供科学依据。方法:回顾性分析2021年11月15日至2022年8月14日该院收治的354例急性缺血性脑卒中患者的临床资料,根据治疗方案分为对照组(使用基础治疗)和观察组(在对照组基础上联合应用依达拉奉右莰醇)。比较两组患者的美国国立卫生院卒中量表评分(NIHSS)、改良Rankin量表评分(mRS)、吞咽功能评分、成本-效用比、质量调整生命年(QALY)等指标。通过单因素敏感性分析和概率敏感性分析,观察各参数变量对研究结果稳定性的影响。结果:治疗后,观察组患者的mRS评分、吞咽功能评分低于对照组,NIHSS评分降低幅度大于对照组,差异均有统计学意义(P<0.05)。观察组治疗方案相较于对照组治疗方案的增量成本-效用比为44649.51元/QALY,小于本研究设定的支付意愿阈值(242928元)。单因素敏感性分析、概率敏感性分析的结果同基础分析结果保持一致。结论:针对急性缺血性脑卒中患者,在基础治疗的情况下联合应用依达拉奉右莰醇可以有效提高治疗综合效益,并且更具有药物经济学优势。OBJECTIVE:To evaluate the efficacy and economic value of edaravone dexcamphorol in the treatment of acute ischemic stroke based on real-world data,so as to provide scientific basis for rational drug use in clinical treatment of stroke and government decision-making in China.METHODS:Clinical data of 354 patients with acute ischemic stroke admitted into the hospital from Nov.15th,2021 to Aug.14th,2022 were retrospectively analyzed and divided into the control group(with basic treatment)and observation group(combined with edaravone dexcamphorol on the basis of control group)according to treatment regimen.The National Institutes of Health Stroke Scale score(NIHSS),Modified Rankin Scale score(mRS),swallowing function score,cost-effectiveness ratio,qubornality-adjusted life years(QALY)of two groups were compared.The influence of each parameter variable on stability of the research results was observed by single factor sensitivity analysis and probability sensitivity analysis.RESULTS:After treatment,the mRS score and swallowing function score of the observation group were lower than those of the control group,and the decrease of NIHSS score was greater than that of control group,with statistically significant differences(P<0.05).Compared with the control group,the incremental cost-effectiveness ratio of treatment regimen in the observation group was 44649.51 yuan/QALY,lower than the willingness to pay threshold(242928 yuan)set in the study.Results of single factor sensitivity analysis and probability sensitivity analysis were consistent with the results of basic analysis.CONCLUSIONS:For patients with acute ischemic stroke,the combination of edaravone dexcamphorol in the context of basic therapy can effectively improve the overall benefit of treatment and has more pharmacoeconomic advantages.

关 键 词：药物经济学评价 急性缺血性脑卒中 依达拉奉右莰醇 敏感性分析 

分 类 号：R956[医药卫生—药学]